Spinal Muscular Atrophy awareness grows in Brazil and Mexico

Spinal Muscular Atrophy (SMA), a rare genetic condition caused by alterations in the SMN1 gene, is the focus of recent medical awareness efforts in Brazil and Mexico. The disease affects motor neurons responsible for voluntary movements and vital functions such as breathing and swallowing.

In Brazil, it is estimated that approximately 1,800 people live with the condition. In Mexico, the number is estimated to be between 2,000 and 2,300 people. SMA is classified into several types based on the age of onset and motor milestones, ranging from severe infantile forms (Types 0 and I) to adult-onset versions (Type IV).

Medical experts emphasize that early diagnosis through genetic testing is critical for accessing treatments that can improve quality of life. While treatments did not exist a decade ago, new intravenous, oral, and intrathecal therapies are now available to help produce the essential SMN protein. In Mexico, these innovative drugs are expected to be included in the basic formulary of public health institutions starting in 2025.